Methionine-producing tumor micro(be) environment fuels growth of solid tumors.


Journal

Cellular oncology (Dordrecht)
ISSN: 2211-3436
Titre abrégé: Cell Oncol (Dordr)
Pays: Netherlands
ID NLM: 101552938

Informations de publication

Date de publication:
Dec 2023
Historique:
accepted: 17 05 2023
medline: 6 12 2023
pubmed: 15 6 2023
entrez: 15 6 2023
Statut: ppublish

Résumé

Recent studies have uncovered the near-ubiquitous presence of microbes in solid tumors of diverse origins. Previous literature has shown the impact of specific bacterial species on the progression of cancer. We propose that local microbial dysbiosis enables certain cancer phenotypes through provisioning of essential metabolites directly to tumor cells. 16S rDNA sequencing of 75 patient lung samples revealed the lung tumor microbiome specifically enriched for bacteria capable of producing methionine. Wild-type (WT) and methionine auxotrophic (metA mutant) E. coli cells were used to condition cell culture media and the proliferation of lung adenocarcinoma (LUAD) cells were measured using SYTO60 staining. Further, colony forming assay, Annexin V Staining, BrdU, AlamarBlue, western blot, qPCR, LINE microarray and subcutaneous injection with methionine modulated feed were used to analyze cellular proliferation, cell-cycle, cell death, methylation potential, and xenograft formation under methionine restriction. Moreover, C Our results show bacteria found locally within the tumor microenvironment are enriched for methionine synthetic pathways, while having reduced S-adenosylmethionine metabolizing pathways. As methionine is one of nine essential amino acids that mammals are unable to synthesize de novo, we investigated a potentially novel function for the microbiome, supplying essential nutrients, such as methionine, to cancer cells. We demonstrate that LUAD cells can utilize methionine generated by bacteria to rescue phenotypes that would otherwise be inhibited due to nutrient restriction. In addition to this, with WT and metA mutant E. coli, we saw a selective advantage for bacteria with an intact methionine synthetic pathway to survive under the conditions induced by LUAD cells. These results would suggest that there is a potential bi-directional cross-talk between the local microbiome and adjacent tumor cells. In this study, we focused on methionine as one of the critical molecules, but we also hypothesize that additional bacterial metabolites may also be utilized by LUAD. Indeed, our radiolabeling data suggest that other biomolecules are shared between cancer cells and bacteria. Thus, modulating the local microbiome may have an indirect effect on tumor development, progression, and metastasis.

Sections du résumé

BACKGROUND BACKGROUND
Recent studies have uncovered the near-ubiquitous presence of microbes in solid tumors of diverse origins. Previous literature has shown the impact of specific bacterial species on the progression of cancer. We propose that local microbial dysbiosis enables certain cancer phenotypes through provisioning of essential metabolites directly to tumor cells.
METHODS METHODS
16S rDNA sequencing of 75 patient lung samples revealed the lung tumor microbiome specifically enriched for bacteria capable of producing methionine. Wild-type (WT) and methionine auxotrophic (metA mutant) E. coli cells were used to condition cell culture media and the proliferation of lung adenocarcinoma (LUAD) cells were measured using SYTO60 staining. Further, colony forming assay, Annexin V Staining, BrdU, AlamarBlue, western blot, qPCR, LINE microarray and subcutaneous injection with methionine modulated feed were used to analyze cellular proliferation, cell-cycle, cell death, methylation potential, and xenograft formation under methionine restriction. Moreover, C
RESULTS/DISCUSSION CONCLUSIONS
Our results show bacteria found locally within the tumor microenvironment are enriched for methionine synthetic pathways, while having reduced S-adenosylmethionine metabolizing pathways. As methionine is one of nine essential amino acids that mammals are unable to synthesize de novo, we investigated a potentially novel function for the microbiome, supplying essential nutrients, such as methionine, to cancer cells. We demonstrate that LUAD cells can utilize methionine generated by bacteria to rescue phenotypes that would otherwise be inhibited due to nutrient restriction. In addition to this, with WT and metA mutant E. coli, we saw a selective advantage for bacteria with an intact methionine synthetic pathway to survive under the conditions induced by LUAD cells. These results would suggest that there is a potential bi-directional cross-talk between the local microbiome and adjacent tumor cells. In this study, we focused on methionine as one of the critical molecules, but we also hypothesize that additional bacterial metabolites may also be utilized by LUAD. Indeed, our radiolabeling data suggest that other biomolecules are shared between cancer cells and bacteria. Thus, modulating the local microbiome may have an indirect effect on tumor development, progression, and metastasis.

Identifiants

pubmed: 37318751
doi: 10.1007/s13402-023-00832-7
pii: 10.1007/s13402-023-00832-7
pmc: PMC10697899
doi:

Substances chimiques

Methionine AE28F7PNPL
Racemethionine 73JWT2K6T3
S-Adenosylmethionine 7LP2MPO46S

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1659-1673

Subventions

Organisme : NCI NIH HHS
ID : R01 CA193220
Pays : United States
Organisme : CIHR
ID : 143345
Pays : Canada
Organisme : NIH HHS
ID : R01CA193220
Pays : United States
Organisme : CIHR
ID : Frederick Banting and Charles Best Canada Graduate Scholarships
Pays : Canada

Informations de copyright

© 2023. The Author(s).

Références

Cell Res. 2020 Jun;30(6):492-506
pubmed: 32433595
Front Genet. 2019 Mar 06;10:138
pubmed: 30894871
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Science. 2018 Mar 23;359(6382):1366-1370
pubmed: 29567708
Mol Syst Biol. 2006;2:2006.0008
pubmed: 16738554
J Thorac Oncol. 2015 Jul;10(7):974-84
pubmed: 26134219
Exp Mol Med. 2019 Dec 11;51(12):1-15
pubmed: 31827064
Trends Cancer. 2020 Mar;6(3):192-204
pubmed: 32101723
Nature. 2020 Mar;579(7800):567-574
pubmed: 32214244
Oncogene. 2009 Apr 30;28(17):1928-38
pubmed: 19330024
Cancer J. 2014 May-Jun;20(3):181-9
pubmed: 24855005
Physiol Rev. 2018 Apr 1;98(2):781-811
pubmed: 29488821
Oral Dis. 2017 Apr;23(3):276-286
pubmed: 27219464
Lancet Oncol. 2017 Jan;18(1):31-41
pubmed: 27932067
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
Sci Rep. 2018 May 24;8(1):8076
pubmed: 29795412
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Biomed Res Int. 2019 Jun 24;2019:2025636
pubmed: 31341890
Cancer Lett. 2018 Feb 28;415:40-48
pubmed: 29197615
Nat Rev Cancer. 2019 Jan;19(1):9-31
pubmed: 30532012
Nat Commun. 2019 Nov 28;10(1):5438
pubmed: 31780666
Cell Death Dis. 2021 Dec 3;12(12):1127
pubmed: 34862383
Front Physiol. 2016 Dec 09;7:606
pubmed: 28018236
Clin Med (Lond). 2017 Dec;17(6):525-529
pubmed: 29196353
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Gut Microbes. 2012 Jan-Feb;3(1):4-14
pubmed: 22356853
Nature. 2018 Jan 24;553(7689):446-454
pubmed: 29364287
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Nat Commun. 2019 Oct 3;10(1):4505
pubmed: 31582752
Trends Immunol. 2018 Sep;39(9):712-723
pubmed: 29843959
Nat Commun. 2017 Jun 06;8:15393
pubmed: 28585563
Clin Med Insights Circ Respir Pulm Med. 2019 Jul 31;13:1179548419862790
pubmed: 31391784
Cancers (Basel). 2020 Jun 02;12(6):
pubmed: 32498338
Microbiome. 2018 Sep 17;6(1):163
pubmed: 30223892
Nat Rev Cancer. 2019 Jul;19(7):371-376
pubmed: 31186547
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Science. 2020 Sep 18;369(6510):1481-1489
pubmed: 32792462
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Genome Biol. 2018 Aug 24;19(1):123
pubmed: 30143034
Sci Rep. 2019 Sep 6;9(1):12838
pubmed: 31492894
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
Synth Biol (Oxf). 2020 Sep 03;5(1):ysaa015
pubmed: 33381654
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
Infect Immun. 2004 Dec;72(12):7247-56
pubmed: 15557650
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040

Auteurs

Alexis A Vega (AA)

Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, USA.
Brown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA.

Erin A Marshall (EA)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.

Avery J C Noonan (AJC)

Genome Science and Technology Program, University of British Columbia, Vancouver, BC, Canada.
ECOSCOPE Training Program, University of British Columbia, Vancouver, BC, Canada.

Fernando Sergio Leitao Filho (FSL)

Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.

Julia Yang (J)

Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.

Greg L Stewart (GL)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.

Fraser D Johnson (FD)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.

Emily A Vucic (EA)

NYU Langone Medical Center, New York, NY, USA.

Michelle E Pewarchuk (ME)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.

Parag P Shah (PP)

Brown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA.

Brian F Clem (BF)

Department of Biochemistry and Molecular Genetics, University of Louisville, Louisville, KY, USA.
Brown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA.

Corey Nislow (C)

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.

Stephen Lam (S)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.

William W Lockwood (WW)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Steven J Hallam (SJ)

Genome Science and Technology Program, University of British Columbia, Vancouver, BC, Canada.
ECOSCOPE Training Program, University of British Columbia, Vancouver, BC, Canada.
Department of Microbiology & Immunology, University of British Columbia, Vancouver, BC, Canada.
Bioinformatics Program, University of British Columbia, Vancouver, BC, Canada.
Biofactorial High-Throughput Biology Facility, University of British Columbia, Vancouver, BC, Canada.

Janice M Leung (JM)

Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, BC, Canada.

Levi J Beverly (LJ)

Brown Cancer Center, University of Louisville School of Medicine, 505 S. Hancock St. Rm 204, Louisville, KY, 40202, USA. Levi.Beverly@Louisville.edu.

Wan L Lam (WL)

Integrative Oncology, BC Cancer Research Centre, Vancouver, BC, Canada.
Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada.
Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH